Clinical Efficacy of the Probiotic <i>Weissella cibaria</i> CMU in Adults with Gingivitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Periodontal disease results from dysbiotic oral biofilms and the host's inflammatory response. Given the limitations of conventional therapies, this study aimed to evaluate the efficacy and safety of <i>Weissella cibaria</i> CMU (OraCMU) in improving gingival inflammation in individuals with gingivitis and incipient periodontitis. In this randomized, double-blind, placebo-controlled trial, 80 participants received either OraCMU tablets (2.0 × 10<sup>8</sup> CFU/g; <i>n</i> = 40) or placebo (<i>n</i> = 40) twice daily for 8 weeks. The primary outcome was the gingival index (GI), and secondary outcomes included bleeding on probing (BOP), probing depth, clinical attachment level, gingival recession, plaque index, inflammation-related proteins, and oral microbiota. Clinical parameters were assessed at six preselected index teeth (#16, 12, 24, 32, 36, and 44). At week 8, the probiotic group showed significantly greater reductions in GI (-0.19 ± 0.03 vs. -0.08 ± 0.04; <i>P</i> = .035) and BOP (-7.74 ± 1.54 vs. -2.82 ± 1.60; <i>P</i> = .030) compared with the placebo group. Inflammatory markers, including fibroblast growth factor-5 (<i>P</i> = .003), thymic stromal lymphopoietin (<i>P</i> = .017), and the receptor activator of nuclear factor κB ligand/osteoprotegerin ratio (<i>P</i> = .021), were significantly decreased. The levels of <i>Porphyromonas gingivalis</i> (<i>P</i> = .001), <i>Treponema denticola</i> (<i>P</i> = .005), and <i>Prevotella intermedia</i> (<i>P</i> = .046) were also significantly reduced, while <i>Weissella</i> increased (<i>P</i> < .001) in the probiotic group. Eight-week supplementation with OraCMU improved gingival health and modulated the oral microbiota and inflammatory response. No serious adverse events were reported during the study period. These findings support the potential clinical utility of OraCMU as a probiotic adjunct for managing gingivitis.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Food
Published
2026-03-12
DOI
https://doi.org/10.1177/1096620x261430298
Primary Topic
Oral microbiology and periodontitis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Efficacy of the Probiotic Weissella cibaria CMU in Adults with Gingivitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Mi-Sun Kang, Keon-Il Yang, Hee-Won Jeon, Sang-Joun Yu et al.
Journal of Medicinal Food
Oral microbiology and periodontitis research
article

Clinical Efficacy of the Probiotic Weissella cibaria CMU in Adults with Gingivitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Mi-Sun Kang, Keon-Il Yang, Hee-Won Jeon, Sang-Joun Yu, Won-Pyo Lee
article en

Abstract

Periodontal disease results from dysbiotic oral biofilms and the host's inflammatory response. Given the limitations of conventional therapies, this study aimed to evaluate the efficacy and safety of <i>Weissella cibaria</i> CMU (OraCMU) in improving gingival inflammation in individuals with gingivitis and incipient periodontitis. In this randomized, double-blind, placebo-controlled trial, 80 participants received either OraCMU tablets (2.0 × 10<sup>8</sup> CFU/g; <i>n</i> = 40) or placebo (<i>n</i> = 40) twice daily for 8 weeks. The primary outcome was the gingival index (GI), and secondary outcomes included bleeding on probing (BOP), probing depth, clinical attachment level, gingival recession, plaque index, inflammation-related proteins, and oral microbiota. Clinical parameters were assessed at six preselected index teeth (#16, 12, 24, 32, 36, and 44). At week 8, the probiotic group showed significantly greater reductions in GI (-0.19 ± 0.03 vs. -0.08 ± 0.04; <i>P</i> = .035) and BOP (-7.74 ± 1.54 vs. -2.82 ± 1.60; <i>P</i> = .030) compared with the placebo group. Inflammatory markers, including fibroblast growth factor-5 (<i>P</i> = .003), thymic stromal lymphopoietin (<i>P</i> = .017), and the receptor activator of nuclear factor κB ligand/osteoprotegerin ratio (<i>P</i> = .021), were significantly decreased. The levels of <i>Porphyromonas gingivalis</i> (<i>P</i> = .001), <i>Treponema denticola</i> (<i>P</i> = .005), and <i>Prevotella intermedia</i> (<i>P</i> = .046) were also significantly reduced, while <i>Weissella</i> increased (<i>P</i> < .001) in the probiotic group. Eight-week supplementation with OraCMU improved gingival health and modulated the oral microbiota and inflammatory response. No serious adverse events were reported during the study period. These findings support the potential clinical utility of OraCMU as a probiotic adjunct for managing gingivitis.

Journal of Medicinal Food
Korea Pharma (South Korea) (KR), Chosun University Dental Hospital (KR)
Good health and well-being
Openalex Percentile: Top 26%
Oral microbiology and periodontitis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.